quinazolines has been researched along with dasatinib in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (11.86) | 29.6817 |
| 2010's | 49 (83.05) | 24.3611 |
| 2020's | 3 (5.08) | 2.80 |
| Authors | Studies |
|---|---|
| Million, RP | 1 |
| Gautschi, O; Lee, D | 1 |
| Curtiss, FR | 1 |
| Saad, F | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Yamada, Y; Yoshida, T | 1 |
| Clynes, M; McMahon, G; O'Connor, R; Roche, S | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 2 |
| Dempke, W; Zippel, R | 1 |
| Merchant, NB; Nagaraj, NS; Washington, MK | 1 |
| Egloff, AM; Grandis, JR | 1 |
| Eadens, M; Messersmith, W; Puls, LN | 1 |
| Geoerger, B; Leblond, P | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Bareford, MD; Cruickshanks, N; Dai, Y; Dent, P; Grant, S; Hamed, HA; Hubbard, N; Mitchell, C; Tang, Y; Tye, G; Yacoub, A | 1 |
| Baergen, RN; Boeck, M; Christos, P; Chuang, E; Cigler, T; Cobham, MV; Donovan, D; Jain, S; Lam, C; Lane, ME; Mittal, V; Moore, A; O'Loughlin, J; Rafii, S; Schneider, S; Swistel, A; Vahdat, LT; Ward, MM; Wiener, N | 1 |
| Ansén, S; Bass, AJ; Beer, DG; Brace, LE; Brambilla, C; Brambilla, E; Brustugun, OT; Cho, J; Clement, JH; Deng, X; Dutt, A; Eck, MJ; Gabler, F; Gray, NS; Greulich, H; Groen, H; Hammerman, PS; Hanna, M; Hatton, C; Haura, EB; Helland, A; Heuckmann, JM; Heynck, S; Janne, PA; Johnson, BE; Koker, M; Lawrence, MS; Leenders, F; Lim, SM; Lin, W; Lorimier, P; Meyerson, M; Moch, H; Onofrio, RC; Peifer, M; Petersen, I; Querings, S; Ramos, AH; Rauh, D; Salvesen, HB; Seidel, D; Sietsma, H; Simard, JR; Soltermann, A; Sos, ML; Stoelben, E; Thomas, RK; Timens, W; Tsao, MS; Winckler, W; Wolf, J; Wong, KK; Woods, BA; Xu, C; Zander, T; Zhang, J; Zhou, W | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Chang, AY; Wang, M | 1 |
| Elmquist, WF; Mittapalli, RK; Sane, R | 1 |
| Broniscer, A; Gajjar, A; Kaste, SC; Kaufman, RA | 1 |
| Baker, JN; Baker, SD; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Huang, J; Kaste, SC; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panetta, JC; Stewart, CF; Wetmore, C | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Cai, J; Chen, J; Ji, M; Sun, M; Wang, P; Wu, X; Zong, X | 1 |
| de Wispelaere, M; LaCroix, AJ; Yang, PL | 1 |
| Ashworth, A; Campbell, J; Herrera-Abreu, MT; Knowles, MA; Pearson, A; Shnyder, SD; Turner, NC | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Dai, B; Fang, B; Gao, W; Hofstetter, WL; Lu, H; Meng, J; Minna, J; Roth, JA; Swisher, SG; Wang, L; Wu, S | 1 |
| Ding, JF; Zhong, DF | 1 |
| Barth, C; Massard, C; Vignot, S | 1 |
| Carducci, MA; Chi, KN; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Kavsak, P; Kollmannsberger, CK; Mukherjee, SD; Siu, LL; Smith, DC; Spreafico, A; Sridhar, SS; Sukhai, MA; Takebe, N; Wang, L; Wong, TS | 1 |
| Cho, H; Gray, NS; Liu, S; Vetter, ML; Wang, J; Yang, PL; Zhang, J; Zhang, W; Zhang, Z | 1 |
| Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W | 1 |
| Bustos, D; Kirkpatrick, DS; Lin, E; Nicholes, K; Settleman, J; Song, Q; Stephan, JP; Wilson, C | 1 |
| Jean-Claude, BJ; Larroque-Lombard, AL; Peyrard, L; Rachid, Z; Rao, S; Thauvin, C; Williams, C | 1 |
| Bianco, R; Brillante, S; Cosconati, S; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Marciano, R; Montuori, N; Orsini, RC; Parsons, SJ; Raimondo, L; Randazzo, A; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Booth, L; Chen, J; Dent, P; Leon, D; McGuire, WP; Poklepovic, A; Roberts, JL; Tavallai, M; Webb, T | 1 |
| Mehra, R; Zibelman, M | 1 |
| Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A | 1 |
| Li, L; Shao, Z; Wang, Z; Xie, H; Yang, F; Zhou, N | 1 |
| Chang, HH; Coumar, MS; Hsieh, HP; Kuo, CC; Shiao, HY; Singh, VK | 1 |
| Batliner, J; Fey, MF; Gautschi, O; Gugger, M; Rothschild, SI; Tschan, MP | 1 |
| Erbacher, I; Gotham, D; Harada, R; Hill, A; Meldrum, J; Redd, C | 1 |
| Jean-Claude, B; Thibault, B | 1 |
| Li, Y; Liu, D; Quan, Y; Wu, B; Wu, Y; Zhang, D; Zhang, X | 1 |
| Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD | 1 |
| Bracho, O; Burns, SS; Chang, LS; Copik, AJ; Dinh, CT; Fernandez-Valle, C; Franco, MC; Fuse, MA; Liu, XZ; Mittal, R; Plati, SK; Shen, R; Soulakova, JN; Telischi, FF; Yan, D | 1 |
| Usui, N | 1 |
| Broniscer, A; Merchant, TE; Nguyen, R; Onar-Thomas, A; Patay, Z; Pierson, CR | 1 |
| Komada, F | 1 |
| Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D | 1 |
| Abdelhameed, AS; Al-Shakliah, NS; Alanazi, AM; AlRabiah, H; Attwa, MW; Hassan, ES | 1 |
| Abdelhameed, AS; Alanazi, AM; AlRabiah, H; Alruqi, OS; Attia, MI; Attwa, MW | 1 |
| Aure, MR; Engebraaten, O; Haugen, MH; Hongisto, V; Kristensen, VN; Leivonen, SK; Mælandsmo, GM; Normann, LS; Sahlberg, KK; Tahiri, A | 1 |
14 review(s) available for quinazolines and dasatinib
| Article | Year |
|---|---|
Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Topics: Benzodioxoles; Clinical Trials, Phase I as Topic; Dasatinib; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Thiazoles | 2006 |
Src as a therapeutic target in men with prostate cancer and bone metastases.
Topics: Antineoplastic Agents; Benzodioxoles; Bone Neoplasms; Dasatinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Receptors, Androgen; src-Family Kinases; Thiazoles | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines | 2010 |
[SRC kinases in tumor therapy].
Topics: Aniline Compounds; Benzodioxoles; Cell Physiological Phenomena; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; DNA Mutational Analysis; Drug Delivery Systems; Enzyme Activation; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2010 |
Current status of SRC inhibitors in solid tumor malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
An update on dual Src/Abl inhibitors.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2012 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
[Bone targeted therapies: new agents].
Topics: Aniline Compounds; Benzodioxoles; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Dasatinib; Diphosphonates; Humans; Molecular Targeted Therapy; Nitriles; Parathyroid Hormone-Related Protein; Pyrimidines; Quinazolines; Quinolines; RANK Ligand; Receptors, Chemokine; src-Family Kinases; Thiazoles; Transforming Growth Factor beta1 | 2013 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk | 2016 |
9 trial(s) available for quinazolines and dasatinib
| Article | Year |
|---|---|
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Count; Cohort Studies; Dasatinib; Female; Hemangioblasts; Hematopoietic Stem Cells; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Thiazoles; Trastuzumab; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Follow-Up Studies; Glioma; Humans; Infant; Knee Joint; Magnetic Resonance Imaging; Male; Osteonecrosis; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiography; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Glioma; Humans; Male; Piperidines; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Collagen Type I; Dasatinib; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; src-Family Kinases; Taxoids; Thiazoles; Treatment Outcome | 2014 |
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Brain; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Female; Glioma; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Male; Piperidines; Quinazolines; Radiotherapy, Conformal; Stroke; Tumor Burden | 2017 |
36 other study(ies) available for quinazolines and dasatinib
| Article | Year |
|---|---|
Impact of genetic diagnostics on drug development strategy.
Topics: Antineoplastic Agents; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Gefitinib; Genetic Testing; Humans; Neoplasms; Pharmacogenetics; Pyrimidines; Quinazolines; Thiazoles | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; src-Family Kinases; Thiazoles | 2010 |
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dasatinib; Humans; Lapatinib; Limit of Detection; Mass Spectrometry; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sensitivity and Specificity; Thiazoles | 2009 |
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Response to combined molecular targeting: defining the role of P-STAT3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Death; Cell Line, Transformed; Cell Transformation, Neoplastic; Checkpoint Kinase 1; Dasatinib; Female; Fibroblasts; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Protease Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-fyn; Proto-Oncogene Proteins c-yes; Pyrimidines; Quinazolines; Radiation Tolerance; src-Family Kinases; Thiazoles | 2011 |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Dasatinib; Discoidin Domain Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; src-Family Kinases; Thiazoles | 2011 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Brain; Cell Line; Dasatinib; Dogs; Drug Delivery Systems; Emulsions; Erlotinib Hydrochloride; Humans; Mice; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Solubility; Tetrahydroisoquinolines; Thiazoles | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
Topics: Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Design; HCT116 Cells; Humans; Inhibitory Concentration 50; K562 Cells; Models, Chemical; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; src-Family Kinases; Thiazoles; U937 Cells | 2013 |
The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.
Topics: Antibodies, Monoclonal; Benzodioxoles; Blotting, Northern; Blotting, Western; Cell Survival; Dasatinib; Dengue Virus; Dimethyl Sulfoxide; DNA Primers; HEK293 Cells; Humans; Mycophenolic Acid; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Pyrimidines; Quinazolines; Replicon; RNA Interference; RNA, Viral; Thiazoles; Virus Replication | 2013 |
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
Topics: Animals; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gefitinib; Heterografts; High-Throughput Screening Assays; Humans; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2013 |
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor Binding Protein 2; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Fluorescent visualization of Src by using dasatinib-BODIPY.
Topics: Animals; Benzodioxoles; Boron Compounds; Cell Line; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Fluorescence; Humans; Mice; Microscopy, Fluorescence; Molecular Probes; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; Structure-Activity Relationship; Thiazoles | 2014 |
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles | 2014 |
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mutation; Pyrimidines; Quinazolines; Signal Transduction; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
Topics: Animals; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Drug Design; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; src-Family Kinases; Thiazoles; Transplantation, Heterologous | 2015 |
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; RNA Interference; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mice, Nude; Mutation; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; RNA Interference; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2016 |
[The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells].
Topics: Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2016 |
Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Topics: Allosteric Site; Antineoplastic Agents; Binding Sites; Catalytic Domain; Cell Proliferation; Dasatinib; Databases, Chemical; Drug Combinations; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; K562 Cells; Molecular Dynamics Simulation; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Quinazolines; Thermodynamics | 2017 |
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Autophagy-Related Protein-1 Homolog; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Dasatinib; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases | 2017 |
Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
Topics: Algorithms; Antineoplastic Agents; Bortezomib; Commerce; Cost-Benefit Analysis; Dasatinib; Drug Costs; Drugs, Generic; England; Everolimus; Gefitinib; Humans; Neoplasms; Quinazolines | 2017 |
Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Movement; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Neoplasm Invasiveness; Ovarian Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; src-Family Kinases; Tumor Cells, Cultured | 2017 |
Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cladribine; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; MCF-7 Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2017 |
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Topics: Anilides; Animals; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dasatinib; Humans; Mice; Neurilemmoma; Neurofibromin 2; Proto-Oncogene Proteins c-met; Pyridines; Quinazolines; Schwann Cells; src-Family Kinases; Xenograft Model Antitumor Assays | 2017 |
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk | 2017 |
[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].
Topics: Adverse Drug Reaction Reporting Systems; Afatinib; Bortezomib; Carbazoles; Cluster Analysis; Crizotinib; Dasatinib; Databases as Topic; Datasets as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Lung Diseases, Interstitial; Molecular Targeted Therapy; Particle Size; Piperidines; Pyrazoles; Pyridines; Quinazolines; Time Factors | 2018 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmustine; Chemoradiotherapy; Dasatinib; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Photons; Progression-Free Survival; Propensity Score; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Snake Venoms; Supratentorial Neoplasms; Temozolomide; Young Adult | 2018 |
Simple and efficient spectroscopic-based univariate sequential methods for simultaneous quantitative analysis of vandetanib, dasatinib, and sorafenib in pharmaceutical preparations and biological fluids.
Topics: Dasatinib; Humans; Pharmaceutical Preparations; Piperidines; Quinazolines; Sorafenib; Spectrophotometry | 2021 |
Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids.
Topics: Calibration; Dasatinib; Humans; Least-Squares Analysis; Piperidines; Quinazolines; Sorafenib; Spectrophotometry | 2022 |
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dasatinib; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2023 |